Sangamo Therapeutics Inc (SGMO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has a cash flow conversion efficiency ratio of -4.565x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.50 Million) by net assets ($6.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Sangamo Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Sangamo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Sangamo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sangamo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sangamo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
0.069x |
|
Abra Information Technologies Ltd
TA:BBYL
|
0.015x |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
-0.003x |
|
Zakłady Lentex SA
WAR:LTX
|
0.038x |
|
GaeaSoft Corp
KQ:051160
|
0.021x |
|
Osmanli Menkul Degerler AS
IS:OSMEN
|
-0.129x |
|
Austral Gold Ltd
AU:AGD
|
0.377x |
|
Pungguk Ethanol Industrial Co. Ltd
KQ:023900
|
0.072x |
Annual Cash Flow Conversion Efficiency for Sangamo Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Sangamo Therapeutics Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Sangamo Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.77 Million | $-67.14 Million | -2.949x | -8.70% |
| 2023-12-31 | $82.89 Million | $-224.84 Million | -2.713x | -257.79% |
| 2022-12-31 | $294.96 Million | $-223.63 Million | -0.758x | -22.00% |
| 2021-12-31 | $375.34 Million | $-233.25 Million | -0.621x | -281.95% |
| 2020-12-31 | $497.37 Million | $169.88 Million | 0.342x | +202.35% |
| 2019-12-31 | $432.74 Million | $-144.40 Million | -0.334x | -429.20% |
| 2018-12-31 | $366.52 Million | $37.15 Million | 0.101x | +70.38% |
| 2017-12-31 | $187.90 Million | $11.18 Million | 0.059x | +112.30% |
| 2016-12-31 | $136.19 Million | $-65.88 Million | -0.484x | -176.07% |
| 2015-12-31 | $192.44 Million | $-33.72 Million | -0.175x | -538.01% |
| 2014-12-31 | $206.63 Million | $-5.67 Million | -0.027x | +82.84% |
| 2013-12-31 | $121.71 Million | $-19.48 Million | -0.160x | -28.53% |
| 2012-12-31 | $64.90 Million | $-8.08 Million | -0.125x | +61.46% |
| 2011-12-31 | $80.13 Million | $-25.89 Million | -0.323x | +24.51% |
| 2010-12-31 | $55.91 Million | $-23.93 Million | -0.428x | -400.74% |
| 2009-12-31 | $71.78 Million | $-6.14 Million | -0.085x | +72.69% |
| 2008-12-31 | $55.40 Million | $-17.34 Million | -0.313x | -40.54% |
| 2007-12-31 | $72.12 Million | $-16.07 Million | -0.223x | +25.05% |
| 2006-12-31 | $48.70 Million | $-14.48 Million | -0.297x | -176.25% |
| 2005-12-31 | $37.81 Million | $-4.07 Million | -0.108x | +65.72% |
| 2004-12-31 | $32.38 Million | $-10.16 Million | -0.314x | -88.44% |
| 2003-12-31 | $44.66 Million | $-7.44 Million | -0.167x | +6.57% |
| 2002-12-31 | $54.25 Million | $-9.67 Million | -0.178x | -140.42% |
| 2001-12-31 | $82.35 Million | $-6.11 Million | -0.074x | -102.14% |
| 2000-12-31 | $66.89 Million | $-2.45 Million | -0.037x | +87.92% |
| 1999-12-31 | $7.90 Million | $-2.40 Million | -0.304x | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more